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INTRODUCTION 
 
Alzheimer's disease (AD) is a severe neurodegenerative 
disease of the human brain, for which there is as yet no 
cure. When a disease modifying therapy becomes 
available, it will be essential to administer this treatment 
in the very earliest stages of the disease, before 
pathological changes in the brain are widespread, 
rendering the treatment ineffective [1]. Thus, 
identifying the presence of AD in the pre-dementia 
‘prodromal’ or even ‘preclinical’ phase is essential [2]. 
Current biomarkers that are able to detect AD in the 
earliest stages are either invasive (i.e. involving a 
lumbar puncture to a cerebrospinal fluid sample) or 
expensive (i.e. involving neuroimaging). Thus, the 
discovery of a reliable non-invasive and low-cost 
biomarker would be an important development with 
implications for the early diagnosis and monitoring of 
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Background: There is increasing evidence that people in the early stages of Alzheimer’s disease (AD) have subtle 
impairments in cognitive inhibition that can be detected by using relatively simple eye-tracking paradigms, but 
these subtle impairments are often missed by traditional cognitive assessments. People with mild cognitive 
impairment (MCI) are at an increased likelihood of dementia due to AD. No study has yet investigated and 
contrasted the MCI subtypes in relation to eye movement performance. Methods: In this work we explore 
whether eye-tracking impairments can distinguish between patients with the amnesic and the non-amnesic 
variants of MCI. Participants were 68 people with dementia due to AD, 42 had a diagnosis of aMCI, and 47 had 
a diagnosis of naMCI, and 92 age-matched cognitively healthy controls. Results: The findings revealed that eye-
tracking can distinguish between the two forms of MCI. Conclusions: The work provides further support for eye-
tracking as a useful diagnostic biomarker in the assessment of dementia.  
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the disease, particularly on a global scale, since invasive 
and/or expensive biomarkers may not be widely 
available.  
 
Eye movements provide a sensitive, low cost and non-
invasive marker of cognitive change or deterioration 
[3,4]. People with AD gradually lose the efficient 
control of attention and develop impairments of both 
inhibitory control and eye movement error-correction 
[5]. Specifically, the inhibition of a gaze-shift towards a 
salient stimulus as well as the ability to direct a 
voluntary gaze-shift away from this stimulus is 
impaired. This difficulty in gaze control may be due to 
cognitive defects of either inhibitory control, working 
memory (WM), or both [6,7]. The error frequency in the 
antisaccade task (AST) also correlates with the severity 
of AD [3]. Importantly, eye movement deficits can 
develop early in the course of the disease, even before 
cognitive deficits are revealed by standard 
neuropsychological tests [3,7]. A critical issue then is 
whether eye-movement impairments are detectable in 
people who are in a preclinical stage of AD and 
therefore at a greater risk of developing clinical 
dementia.   
 
A strong correlation has been reported [8] between 
antisaccade error rate with cortical thinning (brain 
atrophy) in a mild cognitive impairment (MCI) group. 
However, this work did not distinguish between the 
different types of MCI, thus the low and high-risk of 
dementia participants were conflated in their study. In a 
separate study, a group of amnesic MCI (aMCI) 
participants were contrasted to age-matched controls 
who were assessed both using the AST and with fMRI 
to measure structural changes [9]. The fMRI data 
revealed that participants with aMCI showed reduced 
activation in frontal eye fields and increased inhibitory 
errors when performing the AST. Although this work 
supports eye-tracking as a useful diagnostic tool in 
detecting individuals at high risk of dementia, the 
evidence was not conclusive, as there was no direct 
comparison between an aMCI and a non-amnesic MCI 
(naMCI) group. Evidence that saccadic impairment was 
significantly greater in the aMCI group with the higher 
risk for dementia due to AD, in comparison to the 
naMCI group who are at a lower risk, would clearly 
provide more compelling support for the validity of the 
AST as an early diagnostic marker.  
 
A clinically useful biomarker should be able to detect 
subtle signs of impairment in a group of participants at 
higher risk of dementia such as those with MCI. MCI is 
a clinical syndrome characterised by impairments in 
cognition that are worse than would be expected for a 
person of their age. MCI has several outcomes; it can 
lead to dementia if the underlying cause is AD, or other 
types of neurodegenerative conditions; or it may be 
transient, reversible [10] or even static.  People with a 
diagnosis of MCI are at an increased risk of developing 
dementia compared to cognitively healthy adults with 5-
10% of MCI patients progressing to dementia annually 
(see [11]). Traditionally, the clinical syndrome of MCI 
was considered to be a relatively distinct stage of 
dementia since the cognitive deficits were not severe 
enough to impact significantly on the individual’s 
ability to conduct their activities of daily living [12]. 
However, there is a growing consensus [13,1,2] that 
MCI should be considered a prodromal and/or 
preclinical stage between normal cognitive health and 
AD. MCI can be further split into aMCI and naMCI 
types [12]. Those with aMCI experience greater 
memory impairment in comparison to naMCI. Further, 
[14] found evidence that there are structural differences 
between aMCI and naMCI in certain brain regions (the 
largest differences found for the hippocampus and 
entorhinal cortex). This suggests that memory 
differences may be the result of physical changes in the 
brain. Critically, there is a higher conversation rate to 
dementia due to AD for people diagnosed with aMCI, 
than naMCI [15-17]. Thus, people with aMCI are at 
much greater risk of progressing to AD than healthy 
adults or naMCI. No study has yet investigated the 
comparison of MCI subtypes in relation to eye 
movement performance. The principal aim of the 







The latencies for all correct saccades in the antisaccade 
are shown in Figure 1A. A one-way ANOVA on the 
mean antisaccade latencies revealed that there was a 
significant main effect of participant group 
(F(3,238)=13.541;p<.005; η2=.146). AD (N=65; 
mean=404; SD=86; 95% CI=383-427) generated 
significantly longer latencies than the CP group (N=91; 
mean=338ms; SD=84; 95% CI=321 -355; 
t(154)=4.801;p<.0005; d=.77) and the naMCIs (N=46; 
mean=363ms; SD=62; 95% CI=346-381; 
t(109)=2.78;p=.006; d=.53). However, antisaccade 
latencies did not differ between the aMCI (N=40; 
mean=419ms; SD=82; 95% CI=394-444) and the AD 
group (t(103)=.857;p=.394; d=.17). The mean latencies 
of aMCI group were significantly longer than the 
naMCI group (t(84)=3.607;p=.001; d=.79), and the CP 
group (t(129)=5.116;p<.0005; d=.90). The latencies for 
the naMCI did not differ from the CP group 
significantly (t(135)=1.785;p=.077; d=.31). Because age 
was not balanced between the groups we next 
performed an analysis of covariance. The ANCOVA, 
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with a between-subjects factor: group (AD, aMCI, 
naMCI, CP); and a covariate: age, revealed a significant 
main effect of age (F(1,230)=32.115;p<.0005; η2=.123), 
and group (F(3,230)=6.175;p<.0005; η2=.075). 
However, the corrected model, with age as a covariate 
was also significant (F(4,230)=18.087;p<.0005; 
η2=.239), confirming that the group effect remained 
after age was partialled out. To provide further 
verification that age did not affect results we selected a 
subsample of age-matched participants. This age-
matched sample was achieved by excluding the oldest 
AD (N=4) and aMCI (N=3) and the youngest CPs 
(N=22) and naMCI (N=9) participants from the sample.  
An ANOVA confirmed that the groups were matched 
across age (F(3,201)=.800;p=.495; η2=.012). The 
antisaccade latency findings were replicated in this age-
matched subsample. ANOVA revealed a significant 
main effect of participant group for mean antisaccade 
latencies (F(3,201)=7.263;p<.0005; η2=.098). AD 
(N=62; mean=402ms; SD=88; 95% CI=381-425) 
revealed increased latencies in comparison to the CP 
group (N=69; mean=351ms; SD=88; 95% CI=331-374; 
t(129)=3.304;p=.001; d=.58), and the naMCI  group 
(N=37; mean=363; SD=64; 95% CI=343-383; 
t(97)=2.311;p=.023; d=.47). Again, the aMCI (N=37; 
mean=418; SD=83; 95% CI=392-445) did not differ 
from AD (t(97)=.910;p=.365; d=.19). The aMCI group 
revealed significantly longer latencies compared to the 
naMCI group (t(72)=3.160;p=.002; d=.75), and the CP 
group (t(104)=3.811;p<.0005; d=.75). The antisaccade 
latencies for the naMCI group did not differ from CP 
group (t(104)=.759;p=.449; d=.15).  
 
Antisaccade uncorrected errors 
 
Figure 2B shows the mean frequency (%) total number 
of trials with uncorrected errors in each group for the 
antisaccade experiment. A logistic regression [18] was 
fitted to the proportion of uncorrected errors, with 
weights proportional to the number of AST completed 
per participant and a dispersion parameter to account for 
potential higher than anticipated variation in the number 
of uncorrected errors. Estimated log-odds regression 
coefficients, presented in Table 1, identify that the 
proportion of uncorrected errors are significantly lower 
than 50% for all groups, and thereby revealing that there 
was a significant effect on participant group for the 
antisaccade errors (F(3,245)=10.914; p<.0005). The 
distribution of the standardised Pearson residuals did 
not visually appear to satisfy the assumption of the 
normal distribution. However, a one-way ANOVA test 
suggest that the residual contain no further dependence 
on group (F(3,245)=.108; p=.956) and likewise from a 
non-parametric analysis using the Kruskal Wallis H 
Test (H(3)=3.073; p=.381).  
 
As expected, AD (N=68; mean proportion=26; SD=29; 
95% CI=19-33) generated increased errors in 
comparison to the CP group (N=91; mean 
proportion=10; SD=11; 95% CI=8-13; χ2(1)=18.459; 
p<.0005). Critically, the aMCI group (N=42; mean 
proportion=30; SD=30; 95% CI=21-39) generated a 
higher proportion of antisaccade errors compared to the 
naMCI group (N=46; mean proportion=12; SD=11; 
95% CI=9-16; χ2(1)=11.774; p=.001) and the CP group 
(χ2(1)=21.806; p<.0005). However, there was not a 
significant difference in the errors of the aMCI and the 
AD group (χ2(1)=.665; p=.415) and also between the 
naMCI and CP groups (χ2(1)=.588; p=.446). The 
difference between the AD and naMCI was shown to be 
significant (χ2(1)=8.792; p=.003). 
 
An extension to the model that included participant age 
revealed that the group main effect remained significant 
 
 
Figure 1. The eye movement variables for the Alzheimer's disease (AD), amnesic Mild Cognitive Impairment (aMCI), 
non-amnesic Mild Cognitive Impairment (naMCI), and control participants (CP). (A) Antisaccade latencies (left panel); (B) 
Antisaccade uncorrected errors (right panel). 
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(F(3,235)=8.173; p<.0005), whilst age was not 
(F(1,235)=.167; p=.684). To provide further verification 
that age was not a confounding factor, an age-matched 
sample was entered in the analysis. The results, 
presented in Table 1, were essentially replicated. There 
was a significant main effect of participant group for 
antisaccade errors (F(3,207)=9.295; p<.0005). For 
antisaccade errors, the AD (N=64; mean proportion=26; 
SD=28; 95% CI=19-32) revealed an increased error rate 
compared to the CP group (N=69; mean proportion=10; 
SD=10; 95% CI=7-12; χ2(1)=16.945; p<.0005) and the 
naMCI group (N=37; mean proportion=13; SD=12; 
95% CI=9-16; χ2(1)=7.183; p=.007). Again, critically, 
the aMCI group (N=39; mean proportion=30; SD=31; 
95% CI=20-40) revealed a significantly higher 
frequency of errors compared to the naMCI group 
Table 1. Log-odds coefficient estimates for cognitive groups from the weighted logistic regression model 
for the proportion of uncorrected AST errors.  
Group Log-odds SE 95% Confidence Interval Wald 
   Lower Upper Chi-Square 
All participants (N=249), dispersion = 5.361 
AD -1.242 0.1389 -1.515 -0.970 79.973 
aMCI -1.063 0.1699 -1.396 -0.730 39.192 
naMCI -1.974 0.2038 -2.373 -1.574 93.782 
CP -2.176 0.1670 -2.503 -1.848 169.688 
Age matched (N=211), dispersion = 5.645 
AD -1.226 0.1453 -1.511 -0.941 71.218 
aMCI -1.107 0.1827 -1.466 -0.749 36.742 
naMCI -1.959 0.2317 -2.413 -1.505 71.487 
CP -2.266 0.2066 -2.371 -1.861 120.267 




Figure 2. Heatmap plots of the extracted gaze signals in each of participant groups. The x-axis indicates the time since 
saccadic target appearance, and the y-axis presents the aligned horizontal gaze position. The warmer the colour; the higher is the 
gaze point density in the corresponding spatial-temporal location. Note that the longest "comet" tails, reflecting a high proportion of 
uncorrected errors, are evident for the Alzheimer's (AD) and the amnesic Mild Cognitive Impairment (aMCI) groups. The control 
participants (CP) and the non- amnesic MCI have distinctly shorter "comet" tails. 
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(χ2(1)=8.327; p=0.004) and the CP group 
(χ2(1)=17.635; p<.0005). The aMCI group did not 
differ from the AD group (χ2(1)=.258; p=.612 and nor 
did the naMCI group from the CP group (χ2(1)=.976; 
p=0.323). 
 
Further, to confirm whether AST error rate was 
associated with memory decline we performed a series 
of correlations between AST failure rate and FCSRT 
free recall score. Overall there was a negative 
association between AST error rate and FCSRT free 
recall (r(180)=-.480;p<.0005) which indicates that an 
increase in AST errors was associated with poorer free 
recall on the FCSRT task. This association was also 
observed when considering the participant groups 
separately: a significant negative association was found 
between AST error rate and FCSRT free recall within 
AD patients (r(42)=-.430;p=.004), aMCI (r(39)=-
.439;p=.004), and marginally for naMCI (r(44)=-
.288;p=.052). The association was not significant in 
control participants (r(49)=-.166;p=.243). The results 
indicate that AST inhibitory control is associated with 
memory decline in patient groups. 
 
To clarify the spatial-temporal characteristics of the 
extracted signals in the AST, heatmaps of the gaze 
positions of each participant group are displayed in 
Figure 2. The heatmaps that the density and length of 
the “comet” (yellow) tail is shortest for the CP and 
naMCI groups; and longest for the AD and aMCI 
groups. This reflects the findings reported above, that 
the AD and aMCI generated a high proportion of errors 
in the AST which are uncorrected. Fewer of these 
uncorrected errors are seen in the traces of the control 
and naMCI group. In summary, three salient patterns 
emerge: (1) There were a number of reflexive saccades 
to the target location (which should have been inhibited) 
that increased from the level in CP participants, to the 
naMCI patients, to the aMCI patients, and finally 
showing the highest level in the AD patients. (2) 
Similarly, the time cost to correct the mistakes increases 
from the CP participants, to the naMCI patients, to the 
aMCI patients, and finally to the AD patients. Given 
1500 milliseconds since target onset, the naMCI 
patients and the CP participants could correct almost all 
the mistakes, while the AD and aMCI patients have 
more uncorrected mistakes. (3) The CP participants 
revealed a higher proportion of correct antisaccades and 
corrected errors in comparison to the patient groups 




We can summarise the key findings from this work: (1) 
These findings demonstrate for the first time, that the 
AST can discriminate between people with aMCI and 
naMCI; and (2) The findings replicated the previously 
reported impairment in inhibitory control of 
antisaccades in people with dementia due to AD.  
 
These results confirm that the AST is a promising 
biomarker for dementia. Given that people with MCI 
are more likely to develop dementia due to AD than 
cognitively healthy adults, and in particular that people 
with (aMCI) are at the highest risk of progressing to a 
full dementia syndrome, this may also offer an 
additional prognostic tool for predicting which people 
with a diagnosis of MCI are more likely to progress to 
dementia due to AD. Our results support previous 
literature which has also demonstrated that AD [3,5] 
and MCI [8,9] participants are impaired on the AST. 
These findings, when taken together, may therefore 
indicate that people with AD gradually lose the efficient 
control of attention and develop impairments of both 
inhibitory control and eye movement error-correction. 
There is a growing consensus that eye-tracking now 
provides an important opportunity for clinicians to 
detect the very early stages of Alzheimer’s disease, 
during the MCI phase. Several meta-analyses have been 
conducted all conclude that there is a clear excess of 
inhibition errors in AD (e.g. [19]). These findings are 
particularly compelling given the coupling of the 
impairments that have been replicated in these studies.  
For example, one recent study [20] replicated the 
increase in antisaccade errors together with a decrease 
in the frequency of corrected errors. This pattern of 
inhibitory impairment has not been found in other 
neuropsychiatric neurodegenerative such as 
schizophrenia [21] or Parkinson’s disease [5]. There is 
therefore little doubt that eye-tracking offers a highly 
reliable, simple, non-invasive assessment and patient-
friendly tool for the cognitive assessment of dementia. 
In line with previous work, Holden et al [22] have 
shown that aMCI patients also show the increased 
antisaccade error rates. However, as one recent meta-
analysis confirmed, no previous study has yet compared 
the different subtypes of MCI in a direct comparison of 
oculomotor function [19]. Here we show that people 
with aMCI have significant impairment of inhibitory 
control that is similar to AD; whilst people with naMCI 
are relatively unimpaired, with a level of inhibitory 
control that was more similar to the control group. 
 
Our results suggest that inhibitory control of eye 
movement may be one of the earliest biomarkers of the 
onset of AD. Inhibitory control deficits appear to be 
associated with memory decline. There have been 
relatively few studies of antisaccades in MCI, and, to 
our knowledge, no longitudinal studies. In future work, 
the AST could be studied in people with MCI using a 
prospective longitudinal study design. We hypothesise 
that those people with increased antisaccade error rates 
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will be more likely to have poorer memories and may 
be at risk of developing dementia due to AD. Overall, 
our results support the role of the AST as a useful 
supplementary tool for the early detection of decline in 
people with MCI. 
 
Inhibitory error rates in the antisaccade are sensitive to 
memory impairment, but may even precede it in a patient 
with dementia [5]. The results obtained from this study 
demonstrate that eye movements during the AST could 
be used to automatically classify participants as being at a 
higher risk of AD. There are potentially a number of 
practical implications for this observation. With early 
detection of AD, the potential for commencing effective 
interventions earlier are increased.  
 




Participants were men and women between the ages of 
55 and 90, with at least 11 years of education and fluent 
English-speakers. Of these, 68 were people with 
dementia due to AD, 42 had a diagnosis of aMCI, and 
47 had a diagnosis of naMCI.  We also included 92 age-
matched cognitively healthy people to act as control 
participants (see Table 2). Control participants were 
recruited from the local community or were the 
spouse/partner of the AD or MCI participants. All 
participants were white British or European. 
Participants with MCI or dementia due to AD were 
recruited through local memory clinics in the National 
Health Service (NHS) and had received a clinical 
diagnosis following a full assessment with a dementia 
specialist. All those in the dementia group met clinical 
criteria for dementia due to AD, as per NINCDS-
ADRDA criteria [23].  Those with a diagnosis of MCI 
met the following criteria [24]: (1) subjective 
complaints of memory decline (reported by the person 
themselves or an informant); (2) objective memory or 
other cognitive impairment (considered when scores on 
standard cognitive tests were >1.5 SDs below 
age/education adjusted norms) with or without deficits 
in other cognitive domains; (3) intact daily-life 
activities. To subtype the MCI group further into aMCI 
and naMCI, we applied the [24] criteria (see below). 
Participants with intact cognition (as assessed by a 
series of cognitive tasks; see below) were recruited from 
the local community. Participants were not eligible for 
the study if they had a previous history of head trauma, 
stroke, cardiovascular disease, active or past alcohol or 
substance misuse or dependence, or any physical or 
mental condition severe enough to interfere with their 
ability to participate in the study.  Those with a global 
or specific learning disability were also not eligible to 
participate in the study. All participants had the capacity 
to consent to participation in the study and signed 
informed consent. Ethics’ Committee approval was 
granted by Lancaster University and NHS Health 
Research Authority. 
 
Stimuli and tasks 
 
Eye-tracking was assessed using the AST. Cognition 
was assessed the Montreal Cognitive Assessment 
(MoCA: [25]), the Free and Cued Selective Reminding 
Test with Immediate Recall (FCSRT-IR: [26]), and the 
digit and spatial span [27,28]. 













Age 74 (7.7) 74 (7.4) 69(6.9) 69 (7.2) <.0005 
Sex (% male) 50% 41% 57% 43% .297 ns 
MoCA total score 20 (5.7) 21(4.5) 25 (2.2) 28 (1.8) <.0005 
FCSRT – Free Recall 17.32 (12.0) 18.7 (7.7) 32.3 (4.2) 36.1 (5.7) <.0005 
FCSRT - Total 36.2 (14.8) 45.1 (4.4) 47.4 (1.3) 47.8 (0.8) <.0005 
Digit span total 15.6 (4.1) 16.4 (3.7) 16.7 (4.8) 18.7 (4.5) <.0005 
Spatial span total 11.3 (3.1) 12.6 (3.1) 13.0 (2.6) 14.6 (2.8) <.0005 
MoCA - Montreal Cognitive Assessment [25]; Free cued selective reminding task free recall and total score [26]; digit 
span and spatial span [27,28]. 
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Apparatus 
 
We used an EyeLink Desktop 1000 eye-tracker (SR 
Research) with sampling at 500 Hz. Participants sat 55 
cm away from the monitor (60 Hz). Their dominant eye 
was determined using the Miles test [29] and tracked 
accordingly. Experiment Builder software (SR 
Research) was used to control the stimulus events 
during the eye-tracking tasks. 
 
Antisaccade task (AST) 
 
Each antisaccade trial was preceded by a 1 second 
instruction screen stating that the participant should 
look toward the target. A central fixation target central 
fixation was displayed in white on a black background. 
This was displayed for one second. There was a 200ms 
blank interval before the appearance of the saccade 
distractor. The saccade distractor (in red) was then 
presented in a random order 4 degrees away from where 
the fixation target had been either on the left or right 
side for 2 seconds. Participants were asked to fixate at 
the central point then generate the saccade to the 
opposite position of the screen as soon as the distractor 
appeared. There were a total of 24 antisaccade trials in 
AST. 
 
Montreal cognitive assessment (MoCA)  
 
The MoCA is a brief screening tool for Alzheimer’s 
dementia that includes the domains of attention and 
concentration, executive functions, memory, language, 
visuoconstructional skills, conceptual thinking, 
calculations, and orientation. The test generates a 
maximum score of 30; a scores of 26 or more is 
considered normal.  
 
Free Cued Selective Reminding Task Immediate 
Recall (FCSRT-IR) 
 
The International Working Group on Alzheimer’s 
disease [30] recommended the free and cued selective 
reminding test (FCSRT: [26]) to assess memory, as it 
showed high sensitivity and specificity in the 
differentiation of dementia due to AD from healthy 
controls, and aMCI from naMCI (see [12]). Participants 
were asked to memorise line drawings of a set of easily 
recognised objects (e.g., grapes) which belonged to 
unique category cues (e.g., fruit). 16 items to be learned 
were presented four at a time on a card, one picture in 
each quadrant. Participants were asked to search each 
card, then point to and then name aloud each item (e.g., 
grapes) after its cue (fruit) was verbally presented. The 
card was then removed, and the participant immediately 
performed a cued recall of just those four items on the 
basis of the category cue. Participants were reminded of 
any items that were not recalled by presenting the cue 
and the item together (e.g., the vehicle was a train). This 
procedure was repeated for all 16 pictures across the 
four cards. Participants were then given a test phase that 
consisted of three recall trials. Each test was preceded 
by a 20 second counting distractor task. Each recall trial 
consisted of two parts; after two minutes of free recall, 
category cues were provided for items not retrieved 
during the free recall phase. If subjects failed to retrieve 
the item when provided with the category cue, they 
were reminded by the presentation of both the cue and 
the item together. A measure of free recall and a 
measure of cued recall was obtained by calculating the 
correct responses (both out of a total of 48). This task 
has high validity as it has been used extensively in 
informing MCI and AD diagnoses [24]. [24] 
recommends that scores equal to or below 27 on the free 
recall score indicate aMCI, whilst scores of 28 and over 
indicate naMCI. 
 
Digit span  
 
In the digit span task [27,28], which assesses 
phonological memory function, participants were 
verbally presented with strings of single digit numbers. 
Once the string had been presented, the participant was 
asked to recall the digits in the correct serial order. The 
number of digits presented gradually increased during the 
course of the experiment, starting with two and going up 
to a maximum of nine. Two trials were presented at each 
level and a participant must get both correct in order to 
progress to the next level of the task. Participants then 
completed a reverse digit span task where participants 
need to reverse the order of the presented sequence. 
Again, the number of digits presented gradually increased 
from two to eight. Two trials were presented at each level 
with both correct needed in order to progress. A total 
digit span score was then calculated out of 30 by 




In the spatial span task [27,28], participants were 
presented with an array of nine squares. Squares in the 
array were selected one at a time by the experimenter. 
At the end of the sequence, it was the task of the 
participant to indicate the locations of the selected 
squares in the correct serial order. The number of 
squares selected in sequence increased over the course 
of the experiment from two up to a maximum of nine. 
Two trials were presented at each level and a participant 
had to get both correct in order to progress. A reverse 
version of the task was also performed with the 
participant indicating the sequence in the backwards 
order. A measure of total spatial span score was 
calculated out of a total of 32. 
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Data processing 
 
The raw eye tracking data exported from the EyeLink 
DataViewer software were analysed offline in bespoke 
software [31] with the following features: Noise and 
spikes were filtered by removing all the frames where 
the velocity signal was greater than 1,500 deg/s or the 
acceleration signal was greater than 100,000 deg2/sec. 
All the fixations and saccadic events were detected by 
the EyeLink parser. All the saccades extracted for each 
trial as well as a range of spatial and temporal properties 
measured for each saccade were then stored in a table. 
Microsaccades with amplitude less than 0.7 deg were 
filtered from the data. The latency of the saccade was 
measured from the onset of the saccade to the target 
onset. Only the saccades made within the time window 
80-700 ms after target onset (see Figure 3) were 
included to avoid ‘anticipatory saccades’ i.e. saccades 
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